142nd APHA Annual Meeting and Exposition

Annual Meeting Recordings are now available for purchase

302099
Mobile HBV Vaccine Clinic: Innovative community partnerships to improve vaccination rates among API adults in Philadelphia

142nd APHA Annual Meeting and Exposition (November 15 - November 19, 2014): http://www.apha.org/events-and-meetings/annual
Tuesday, November 18, 2014 : 5:10 PM - 5:30 PM

Chari A. Cohen, MPH, DrPH(c) , Department of Public Health Research, Hepatitis B Foundation, Doylestown, PA
Emily Gibble, MPH , Division of Disease Control, Philadelphia Department of Public Health, Philadelphia, PA
Kuan-Lung Daniel Chen, MPH, CPH , Department of Public Health Research, Hepatitis B Foundation, Doylestown, PA
Amy B. Jessop, PhD, MPH , Department of Health Plicy, University of the Sciences in Philadelphia, Philadelphia, PA
Chronic hepatitis B (HBV) is a serious liver infection that disproportionately affects Asians and Pacific Islanders (API), leading to significant health disparities. Due to sociocultural, economic and systemic barriers, up to 75% of infected APIs don’t know they have HBV; and only 10-40% of the highest-risk APIs are vaccinated against HBV. In Philadelphia, a community-based coalition was started to improve rates of HBV screening, vaccination and linkage to care. A targeted community needs assessment found multiple barriers to HBV vaccine among API adults, including lack of a medical home, transportation issues, and stigma associated with visiting free clinics. To address these issues, the coalition started the Mobile HBV Vaccine Clinic. Free HBV vaccine was offered at trusted community sites to anyone who was screened through the coalition found to have no immunity. Vaccine clinics were held weekends and evenings, at churches, community centers, and pharmacies frequented by community members, to enhance participation. In-language written invitations, with follow-up telephone phone reminders were utilized. Philadelphia Department of Public Health provided free vaccine, HepTREC provided guidance for set-up and protocol, and HBF conducted all communication with participants. Additional coalition partners, including pharmacies, social service, and medical student organizations provided volunteers to staff events, including interpreters. Over 18 months, the Mobile HBV Vaccine Clinic provided 417 doses of HBV vaccine at 28 events. 34% of people completed all three doses of the vaccine series. This proved to be a successful model for vaccinating high-risk and hard to reach API adults in Philadelphia. Future considerations include sustainability in a resource constrained environment, and ensuring linguistic and cultural competency.

Learning Areas:

Chronic disease management and prevention
Planning of health education strategies, interventions, and programs
Protection of the public in relation to communicable diseases including prevention or control

Learning Objectives:
Identify barriers to HBV vaccination among Asians and Pacific Islander in Philadelphia. Demonstrate the successes of public-private partnerships to overcome barriers in vaccinating high-risk Asians and Pacific Islanders. Describe the development, activities, successes and challenges associated with running a mobile hepatitis B vaccine clinic.

Keyword(s): Hepatitis B, Asian and Pacific Islanders

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: For the past 15 years I have planned, implemented and evaluated community programs and research projects focusing on hepatitis B and liver cancer. My research focuses on reducing hepatitis B related health disparities, including determining barriers to, and developing culturally competent models for improving health care access. I am co-founder and director of Hep B United Philadelphia, a coalition and campaign to increase testing, vaccination and linkage to care in Asian and Pacific Islander communities.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.